Review of NICE Technology Appraisal Guidance No. 213; Aripiprazole for schizophrenia in people aged 15 to 17 years

The Institute was proposing that the guidance should be incorporated, verbatim, into the ongoing clinical guideline on the recognition and management of schizophrenia presenting up to 18 years of age.

During consultation, the majority of comments received by the Institute agreed with the proposal put forward.  After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.